source
- Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trialNovo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
- Madrigal spends $255 million on multiple MASH drug deals to complement RezdiffraMadrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer…